Movement Alert｜InnoCare Pharma Rises 6.65% in Regular Trading, Self-Developed ADC Drug ICP-B208 Completes First Patient Dosing

Market Focus07-06

On July 6, InnoCare Pharma (09969.HK) rose 6.65% in regular trading, trading at HK$14.03/share, with turnover of HK$72.80 million.

On the news front, InnoCare Pharma announced that its self-developed CDH17-targeting novel ADC innovative drug ICP-B208 has completed first patient dosing, officially marking the drug's entry into the clinical stage. Built on InnoCare's proprietary ADC technology platform, ICP-B208 consists of a humanized anti-CDH17 antibody conjugated via a protease-cleavable linker to a proprietary potent payload, designed to precisely target tumor cells while minimizing off-target effects.

The milestone adds to a series of recent pipeline advances for the company, including the acceptance of a new drug application for orelabrutinib in primary immune thrombocytopenia, Australian approval for orelabrutinib in relapsed/refractory mantle cell lymphoma, and the first subject enrollment in the Phase 1 trial of oral IL-17AA/AF inhibitor ICP-054. The broader Biotechnology sector also saw gains, with REMEGEN up 4.95%, INNOVENT BIO up 5.01%, and SKB BIO up 4.11%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120897847?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-06 10:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120897847","market":"us","top_or_hot":-1,"title":"Movement Alert｜InnoCare Pharma Rises 6.65% in Regular Trading, Self-Developed ADC Drug ICP-B208 Completes First Patient Dosing","media":"Market Focus","content":"<p><p>On July 6, InnoCare Pharma (09969.HK) rose 6.65% in regular trading, trading at HK$14.03/share, with turnover of HK$72.80 million.</p><p>On the news front, InnoCare Pharma announced that its self-developed CDH17-targeting novel ADC innovative drug ICP-B208 has completed first patient dosing, officially marking the drug's entry into the clinical stage. Built on InnoCare's proprietary ADC technology platform, ICP-B208 consists of a humanized anti-CDH17 antibody conjugated via a protease-cleavable linker to a proprietary potent payload, designed to precisely target tumor cells while minimizing off-target effects.</p><p>The milestone adds to a series of recent pipeline advances for the company, including the acceptance of a new drug application for orelabrutinib in primary immune thrombocytopenia, Australian approval for orelabrutinib in relapsed/refractory mantle cell lymphoma, and the first subject enrollment in the Phase 1 trial of oral IL-17AA/AF inhibitor ICP-054. The broader Biotechnology sector also saw gains, with REMEGEN up 4.95%, INNOVENT BIO up 5.01%, and SKB BIO up 4.11%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜InnoCare Pharma Rises 6.65% in Regular Trading, Self-Developed ADC Drug ICP-B208 Completes First Patient Dosing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜InnoCare Pharma Rises 6.65% in Regular Trading, Self-Developed ADC Drug ICP-B208 Completes First Patient Dosing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-06 10:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 6, InnoCare Pharma (09969.HK) rose 6.65% in regular trading, trading at HK$14.03/share, with turnover of HK$72.80 million.</p><p>On the news front, InnoCare Pharma announced that its self-developed CDH17-targeting novel ADC innovative drug ICP-B208 has completed first patient dosing, officially marking the drug's entry into the clinical stage. Built on InnoCare's proprietary ADC technology platform, ICP-B208 consists of a humanized anti-CDH17 antibody conjugated via a protease-cleavable linker to a proprietary potent payload, designed to precisely target tumor cells while minimizing off-target effects.</p><p>The milestone adds to a series of recent pipeline advances for the company, including the acceptance of a new drug application for orelabrutinib in primary immune thrombocytopenia, Australian approval for orelabrutinib in relapsed/refractory mantle cell lymphoma, and the first subject enrollment in the Phase 1 trial of oral IL-17AA/AF inhibitor ICP-054. The broader Biotechnology sector also saw gains, with REMEGEN up 4.95%, INNOVENT BIO up 5.01%, and SKB BIO up 4.11%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09969","symbol_name":"诺诚健华","start_time":0,"source_url":"","article_id":"1120897847","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120897847","pubTimestamp":1783303230,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 6, InnoCare Pharma (09969.HK) rose 6.65% in regular trading, trading at HK$14.03/share, with turnover of HK$72.80 million.On the news front, InnoCare Pharma announced that its self-developed...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09969":"诺诚健华"},"translate_title":"动静快讯|诺诚健华医药常规交易涨6.65%自研ADC药物ICP-B208完成首例患者给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09969":1},"content_text":"On July 6, InnoCare Pharma (09969.HK) rose 6.65% in regular trading, trading at HK$14.03/share, with turnover of HK$72.80 million.On the news front, InnoCare Pharma announced that its self-developed CDH17-targeting novel ADC innovative drug ICP-B208 has completed first patient dosing, officially marking the drug's entry into the clinical stage. Built on InnoCare's proprietary ADC technology platform, ICP-B208 consists of a humanized anti-CDH17 antibody conjugated via a protease-cleavable linker to a proprietary potent payload, designed to precisely target tumor cells while minimizing off-target effects.The milestone adds to a series of recent pipeline advances for the company, including the acceptance of a new drug application for orelabrutinib in primary immune thrombocytopenia, Australian approval for orelabrutinib in relapsed/refractory mantle cell lymphoma, and the first subject enrollment in the Phase 1 trial of oral IL-17AA/AF inhibitor ICP-054. The broader Biotechnology sector also saw gains, with REMEGEN up 4.95%, INNOVENT BIO up 5.01%, and SKB BIO up 4.11%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120897847","isCrawlerRequest":true}